Skip to content
Investors Dashboard
Contact
TwitterFacebookInstagramLinkedinYouTube
  • English
  • Spanish
TwitterFacebookInstagramLinkedinYouTube
  • English
  • Spanish
Pharmamar S.A
Pharmamar S.A.
Pharmamar S.APharmamar S.A
  • About Pharmamar
    • Senior Management
    • Management Team Oncology Unit
    • Board of directors
    • Other Business
    • PharmaMar in the World
    • Awards & Recognition
    • Corporate Responsibility
    • Our History
  • Patients
    • Therapeutic Indications
    • Collaboration with Patient Associations
    • Clinical trial
  • Products
    • YONDELIS®
    • Lurbinectedin
  • Science & Innovation
    • Medical meeting presentations
    • R&D and Innovation
    • Oncology Pipeline
    • Cofinanced Projects
    • Collaboration with Scientific Associations
    • Publications
    • Mechanisms of Action
    • Medical meeting presentations
  • Shareholders and Investors
    • Finantial Information
      • Annual Reports
      • Quarterly Reports
      • Financial Statements
      • Average Period of Payment to Suppliers
    • Notifications sent to CNMV
    • Share Information
      • Share Performance
      • Share Outstanding
      • Dividends
      • Significant Shareholding & Company Owned-Stock
      • Analysts
    • Debt Obligations
    • Presentations
    • General Shareholders Meetings
    • Corporate Governance
      • Corporate Bylaws
      • General Shareholders’ Meeting Regulations
      • Shareholder Agreements
      • Board of Directors
      • Board of Directors Regulation
      • Annual Report on Corporate Governance
      • Annual Director Remuneration Report
      • Board Committees
      • Internal Regulation Governing Conduct
    • Contact
    • Merger PharmaMar-Zeltia
    • Política de Comunicación con Accionistas
  • Newsroom
    • Press Releases
    • Events calendar
    • Multimedia
      • Videos
      • Infographics
    • Medical meeting presentations
    • Corporate Brochure
  • Careers
    • Benefits
    • Send us your CV
    • About Pharmamar
      • Senior Management
      • Management Team Oncology Unit
      • Board of directors
      • Other Business
      • PharmaMar in the World
      • Awards & Recognition
      • Corporate Responsibility
      • Our History
    • Patients
      • Therapeutic Indications
      • Collaboration with Patient Associations
      • Clinical trial
    • Products
      • YONDELIS®
      • Lurbinectedin
    • Science & Innovation
      • Medical meeting presentations
      • R&D and Innovation
      • Oncology Pipeline
      • Cofinanced Projects
      • Collaboration with Scientific Associations
      • Publications
      • Mechanisms of Action
      • Medical meeting presentations
    • Shareholders and Investors
      • Finantial Information
        • Annual Reports
        • Quarterly Reports
        • Financial Statements
        • Average Period of Payment to Suppliers
      • Notifications sent to CNMV
      • Share Information
        • Share Performance
        • Share Outstanding
        • Dividends
        • Significant Shareholding & Company Owned-Stock
        • Analysts
      • Debt Obligations
      • Presentations
      • General Shareholders Meetings
      • Corporate Governance
        • Corporate Bylaws
        • General Shareholders’ Meeting Regulations
        • Shareholder Agreements
        • Board of Directors
        • Board of Directors Regulation
        • Annual Report on Corporate Governance
        • Annual Director Remuneration Report
        • Board Committees
        • Internal Regulation Governing Conduct
      • Contact
      • Merger PharmaMar-Zeltia
      • Política de Comunicación con Accionistas
    • Newsroom
      • Press Releases
      • Events calendar
      • Multimedia
        • Videos
        • Infographics
      • Medical meeting presentations
      • Corporate Brochure
    • Careers
      • Benefits
      • Send us your CV

    annual-report-year-2011-890×510

    You are here:
    1. Home
    2. annual-report-year-2011-890×510
     Dream-Theme — truly premium WordPress themes
    Sobre Pharmamar
    Go to Top